No Data
No Data
Jiangsu Apon Medical Technology (300753.SZ): Currently, they have established cooperation with several well-known private hospitals such as Peking United Family Hospital and Taikang Hospital.
Jiangsu Apon Medical Technology (300753.SZ) stated on the investor interaction platform on September 12 that the company's main business includes pain management and nasal and upper airway management, and it has established private hospital channels, including but not limited to pain pumps, anesthesia depth monitors, nasal care sprays, fixed snoring devices, and medical beauty products. It has already established cooperation with several well-known private hospitals such as Peking United Family Hospital and Taikang Hospital.
Jiangsu Apon Medical Technology (SZSE:300753) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Jiangsu Apon Medical Technology: Half-year report for the year 2024.
Jiangsu Apon Medical Technology: Summary of Half-Year Report in 2024.
Jiangsu Apon Medical Technology (300753.SZ): Net income in the first half of the year was RMB 8.8935 million, a year-on-year increase of 221.31%.
Jiangsu Apon Medical Technology (300753.SZ) announced its 2024 interim report, with revenue of CNY 0.179 billion, down 4.89% year-on-year; net income attributable to shareholders of the listed company was CNY 8.8935 million, up 221.31% year-on-year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was CNY 5.8269 million, up 255.15% year-on-year; basic earnings per share were CNY 0.0706.
Jiangsu Apon Medical Technology (300753.SZ): Some directors and senior management personnel have cumulatively increased their shareholding by 0.6636%.
Jiangsu Apon Medical Technology (300753.SZ) announced on August 6th that as of the disclosure date of this announcement, the shareholding plan has expired and been fully implemented. Some directors and senior executives of the company have increased their holdings by 0.7984 million shares, accounting for 0.6636% of the total share capital of the company, with a total investment of 7.725 million yuan.
No Data
No Data